| Route/form | Estrogen | Dosage | Ref(s) |
|---|---|---|---|
| Oral | Estradiol | 1–2 mg 3x/day | [1] |
| Conjugated estrogens | 1.25–2.5 mg 3x/day | [2] [3] | |
| Ethinylestradiol | 0.15–3 mg/day | [2] [3] [4] | |
| Ethinylestradiol sulfonate | 1–2 mg 1x/week | [5] [3] [6] | |
| Diethylstilbestrol | 1–3 mg/day | [2] [7] | |
| Dienestrol | 5 mg/day | [8] | |
| Hexestrol | 5 mg/day | [8] | |
| Fosfestrol | 100–480 mg 1–3x/day | [9] [10] [4] | |
| Chlorotrianisene | 12–48 mg/day | [2] [8] [11] [4] | |
| Quadrosilan | 900 mg/day | [8] | |
| Estramustine phosphate | 140–1400 mg/day | [12] | |
| Transdermal patch | Estradiol | 2–6x 100 μg/day Scrotal: 1x 100 μg/day |
[13]
[14] [15] |
| IM or SC injection | Estradiol benzoate | 1.66 mg 3x/week | [16] |
| Estradiol dipropionate | 5 mg 1x/week | [16] | |
| Estradiol valerate | 10–40 mg 1x/1–2 weeks | [17] [18] | |
| Estradiol undecylate | 100 mg 1x/4 weeks | [19] [8] | |
| Polyestradiol phosphate | Alone: 160–320 mg 1x/4 weeks With oral EE: 40–80 mg 1x/4 weeks |
[20]
[19] [21] [8] | |
| Estrone | 2–4 mg 2–3x/week | [2] [22] | |
| IV injection | Fosfestrol | 300–1200 mg 1–7x/week | [9] [10] [4] |
| Estramustine phosphate | 240–450 mg/day | [12] [23] | |
| Note: Dosages are not necessarily equivalent. | |||
Template documentationSee also
- Template:Estrogen dosages for breast cancer
- Template:Estrogen dosages for menopausal hormone therapy
- Template:Medications and dosages used in hormone therapy for transgender women
References
- ^ "ESTRACE TABLETS (estradiol tablets, USP)" (PDF). Warner Chilott. U.S. Food and Drug Administration.
- ^ a b c d e Thomas JA, Keenan EJ (6 December 1986). "Estrogens and Antiestrogenic Drugs". Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 135–165. doi: 10.1007/978-1-4684-5036-1_7. ISBN 978-1-4684-5036-1.
- ^ a b c Oettel M (1999). "Estrogens and Antiestrogens in the Male". In Oettel M, Schillinger E (eds.). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Handbook of Experimental Pharmacology. Vol. 135 / 2. Springer Science & Business Media. pp. 505–571. doi: 10.1007/978-3-642-60107-1_25. ISBN 978-3-642-60107-1. ISSN 0171-2004.
- ^ a b c d Martz G (13 March 2013). Die hormonale Therapie maligner Tumoren: Endokrine Behandlungsmethoden des metastasierenden Mamma-, Prostata- und Uterus-Corpuscarcinoms. Springer-Verlag. pp. 51–. ISBN 978-3-642-86282-3.
- ^ Höfling G, Heynemann H (2014). "Die orale Östrogentherapie des fortgeschrittenen Prostatakarzinoms — Anlaß für eine Neubewertung?" [Oral Estrogen Therapy for Advanced Prostate Cancer — Reason for Revaluation?]. Der Urologe B. 38 (2): 165–170. doi: 10.1007/s001310050185. ISSN 0042-1111.
- ^ Wolfgang Hinkelbein; Kurt Miller; Thomas Wiegel (7 March 2013). Prostatakarzinom — urologische und strahlentherapeutische Aspekte: urologische und strahlentherapeutische Aspekte. Springer-Verlag. pp. 91–. ISBN 978-3-642-60064-7.
- ^ Lupulescu A (24 October 1990). "Hormones and Hormonotherapy". Hormones and Vitamins in Cancer Treatment. CRC Press. pp. 33–90. ISBN 978-0-8493-5973-6.
- ^ a b c d e f Günther H. Jacobi; Rudolf Hohenfellner (1 December 1982). Prostate Cancer. Williams & Wilkins. p. 223. ISBN 978-0-683-04354-9.
- ^ a b Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. p. 2104–2105. ISBN 978-0-85369-840-1.
- ^ a b von Bruchhausen F, Dannhardt G, Ebel S, Frahm AW, Hackenthal E, Holzgrabe U (2 July 2013). Hagers Handbuch der Pharmazeutischen Praxis: Band 8: Stoffe E-O. Springer-Verlag. pp. 301–. ISBN 978-3-642-57994-3.
- ^ Dao TL (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Sartorelli AC, Johns DG (eds.). Antineoplastic and Immunosuppressive Agents. pp. 170–192. doi: 10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8.
- ^ a b Perry CM, McTavish D (July 1995). "Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer". Drugs & Aging. 7 (1): 49–74. doi: 10.2165/00002512-199507010-00006. PMID 7579781. S2CID 36725810.
- ^ Ockrim J, Lalani JL, Abel P (October 2006). "Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy". Nature Clinical Practice. Oncology. 3 (10): 552–63. doi: 10.1038/ncponc0602. PMID 17019433. S2CID 6847203.
- ^ Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD (May 2003). "Transdermal estradiol therapy for advanced prostate cancer--forward to the past?". The Journal of Urology. 169 (5): 1735–7. doi: 10.1097/01.ju.0000061024.75334.40. PMID 12686820.
- ^ Re I, Asenjo G, Maximino G, Micheletti L (2005). "Tratamiento del Cáncer de Próstata Avanzado con Estrógenos Transdérmicos Escrotales (ETE)" [Transdermal Scrotal Estrogen Patches (TSEP) in the Treatment of Advanced Prostate Cancer]. Revista Argentina de Urología (in Spanish). 70 (4): 231. ISSN 0325-2531.
- ^ a b "NNR: Products Recently Accepted by the A. M. A. Council on Pharmacy and Chemistry". Journal of the American Pharmaceutical Association (Practical Pharmacy Ed.). 10 (11): 692–694. 1949. doi: 10.1016/S0095-9561(16)31995-8. ISSN 0095-9561.
- ^ "DELESTROGEN (estradiol valerate injection, USP)" (PDF). Par Pharmaceutical, Inc. U.S. Food and Drug Administration.
- ^ Kohli M, Alikhan MA, Spencer HJ, Carter G (2004). "Phase I trial of intramuscular estradiol valerate (I/M-E) in hormone refractory prostate cancer". Journal of Clinical Oncology. 22 (14_suppl): 4726. doi: 10.1200/jco.2004.22.90140.4726. ISSN 0732-183X.
- ^ a b Norman G, Dean ME, Langley RE, Hodges ZC, Ritchie G, Parmar MK, et al. (February 2008). "Parenteral oestrogen in the treatment of prostate cancer: a systematic review". British Journal of Cancer. 98 (4): 697–707. doi: 10.1038/sj.bjc.6604230. PMC 2259178. PMID 18268497.
- ^ "Estradurin Polyestradiol Phosphate". Pharmanovia. Archived from the original on 20 November 2017.
- ^ Cox RL, Crawford ED (December 1995). "Estrogens in the treatment of prostate cancer". The Journal of Urology. 154 (6): 1991–8. doi: 10.1016/s0022-5347(01)66670-9. PMID 7500443.
- ^ "Estrone suspension approval" (PDF). Center for Drug Evaluation and Research. U.S. Food and Drug Administration.
- ^ Bergenheim AT, Henriksson R (February 1998). "Pharmacokinetics and pharmacodynamics of estramustine phosphate". Clinical Pharmacokinetics. 34 (2): 163–72. doi: 10.2165/00003088-199834020-00004. PMID 9515186. S2CID 1943973.